SCHEMBL5872501

SCHEMBL5872501

FC(F)(F)COC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22692805 1.00 NPC1 (0.40) NPC1CA1CA2
SCHEMBL4426666 0.97 NPC1 (0.37) NPC1
SCHEMBL2647631 0.82 ALDH1A1 (0.44)
SCHEMBL2647634 0.82 ALDH1A1 (0.44)
SCHEMBL8077432 0.81
SCHEMBL22692804 0.79 NPC1 (0.41) NPC1
SCHEMBL21621739 0.78 CTSL (0.33)
SCHEMBL24339629 0.76 TSHR (0.31)
SCHEMBL10337190 0.76
SCHEMBL408304 0.76 HTR2C (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699553-B1 SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARM LLC (US) 2023-11-08 EP disclosed
EP-3849968-B1 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) BRISTOL MYERS SQUIBB CO (US) 2022-12-21 EP disclosed
US-20140121243-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2014-05-01 US disclosed
EP-1425318-B1 ACTIVATING ORGANOMETALLIC COMPOSITION FOR THE (CO)POLYMERIZATION OF ALPHA-OLEFINS COMPRISING FLUORINATED CYCLOPENTADIENYL COMPOUNDS VERSALIS SPA (IT) 2013-01-16 EP disclosed
US-7081505-B2 Activating organometallic composition for the (co) polymerization of alpha-olefins comprising fluorinated cyclopentadienyl compounds POLIMERI EUROPA S.P.A. (IT) 2006-07-25 US disclosed
EP-0771822-B1 Catalytic system for the (co)polymerization of alpha-olefins POLIMERI EUROPA SPA (IT) 2005-04-13 EP disclosed
US-20040198934-A1 Activating organometallic composition for the (co) polymerization of alpha-olefins comprising fluorinated cyclopentadienyl compounds POLIMERI EUROPA S.P.A. (IT) 2004-10-07 US disclosed
EP-1425318-A1 ACTIVATING ORGANOMETALLIC COMPOSITION FOR THE (CO)POLYMERIZATION OF ALPHA-OLEFINS COMPRISING FLUORINATED CYCLOPENTADIENYL COMPOUNDS Polimeri Europa S.p.A. (IT) 2004-06-09 EP disclosed
WO-2003010210-A1 ACTIVATING ORGANOMETALLIC COMPOSITION FOR THE (CO)POLYMERIZATION OF ALPHA-OLEFINS COMPRISING FLUORINATED CYCLOPENTADIENYL COMPOUNDS POLIMERI EUROPA S.P.A. (IT) 2003-02-06 WO disclosed
US-6274529-B1 COORDINATION CATALYST CONTAINS METALLOCENE OF HAFNIUM, TITANIUM, OR ZIRCONIUM, AND HETEROCOMPOUND CONTAINING OXYGEN, NITROGEN, SULFUR, AND/OR PHOSPHORUS ENICHEM S.P.A. (IT) 2001-08-14 US disclosed
EP-0771822-A1 Catalytic system for the (co)polymerization of alpha-olefins ENICHEM S.p.A. (IT) 1997-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121243-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE CHRNA3, CHRNB3, CHRNA7 NPC1 2458/4885CA1 1836/4885CA2 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.